# Precision Neuroscience Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/precision-neuroscience

- Industry: Medical Devices & Equipment
- Headquarters: New York, US
- Website: www.precisionneuro.io
- Total disclosed funding: $395M
- Latest round: Series D (Sep 24, 2026)
- Investors on record: 16

## About

Based in New York, US, and founded in 2021 by co-founders Dr. Benjamin Rapoport and Michael Mager (CEO), Precision Neuroscience Corporation, operates as a developer of medical devices that include brain-computer interfaces (BCI). In September 2026, Precision Neuroscience Corporation raised USD 250 million in series D funding led by Pershing Square Capital Management, with participation from Ark Invest, Invus Financial Advisors, Mirae Asset Global Investments, Korea Investment Partners, Hitachi Ventures, JSL Health Capital, B Capital, Mubadala Capital, and Duquesne Family Office. The company will use the funding to advance brain-computer interface technology for paralysis, leveraging its network of clinicians and regulatory experts to support clinical adoption. Precision Neuroscience offers the Layer 7 Cortical Interface for minimally invasive brain–computer interfacing, AI-driven neural data software, and microfabrication foundry services for biocompatible implants supporting neurological treatment and research. The company will use the September 2026 funding to expand its clinical programs, advance its Layer 7 brain-computer interface through further FDA review, and build infrastructure for commercialization.

## Funding rounds

- Series D, Sep 24, 2026, $250M — Mirae Asset Global Investments, Invus Financial Advisors, Korea Investment Partners, Duquesne Family Office, B Capital, Mubadala Capital, Hitachi Ventures, Ark Invest, JSL Health Capital, Pershing Square Foundation
- Series C, Oct 2, 2024, $93M — Steadview Capital Management, Duquesne Family Office, B Capital, General Equity Holdings
- Series B, Dec 5, 2022, $41M — Steadview Capital Management, Draper, Alumni Ventures Group, B Capital, Mubadala Capital, Forepont Capital Partners, re.Mind Capital
- Series A, Apr 16, 2021, $11M — Steadview Capital Management, B Capital

## Investors

- Steadview Capital Management (https://capitalatlas.ai/funds/steadview-capital-management) — Series A, Series B, Series C
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series A, Series B, Series C, Series D
- Draper (https://capitalatlas.ai/funds/draper) — Series B
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series B, Series D
- Forepont Capital Partners (https://capitalatlas.ai/funds/forepont-capital-partners) — Series B
- re.Mind Capital (https://capitalatlas.ai/funds/re-mind-capital) — Series B
- Duquesne Family Office — Series C, Series D
- General Equity Holdings — Series C
- Mirae Asset Global Investments (https://capitalatlas.ai/funds/mirae-asset-global-investments) — Series D
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series D
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series D
- Hitachi Ventures (https://capitalatlas.ai/funds/hitachi-ventures) — Series D
- Ark Invest (https://capitalatlas.ai/funds/ark-invest) — Series D
- JSL Health Capital (https://capitalatlas.ai/funds/jsl-health-capital) — Series D
- Pershing Square Foundation — Series D